- Home
- AKBA vs TTI Comparison
AKBA vs TTI Comparison
Compare AKBA & TTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AKBA | TTI |
|---|---|---|
| Founded | 2007 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 729.1M | 761.0M |
| IPO Year | 2014 | 1990 |
Fundamental Metrics
Financial Performance| Metric | AKBA | TTI |
|---|---|---|
| Price | $1.48 | $7.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $6.25 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 5.0M | 1.8M |
| Earning Date | 11-10-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7085.43 |
| EPS | N/A | ★ 0.92 |
| Revenue | $225,071,000.00 | ★ $618,755,000.00 |
| Revenue This Year | $52.38 | $5.57 |
| Revenue Next Year | $22.45 | $4.58 |
| P/E Ratio | ★ N/A | $8.62 |
| Revenue Growth | ★ 32.49 | 0.17 |
| 52 Week Low | $1.46 | $2.03 |
| 52 Week High | $4.08 | $8.35 |
Technical Indicators
Market Signals| Indicator | AKBA | TTI |
|---|---|---|
| Relative Strength Index (RSI) | 28.25 | 58.55 |
| Support Level | $1.52 | $7.14 |
| Resistance Level | $1.63 | $8.10 |
| Average True Range (ATR) | 0.10 | 0.48 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 1.15 | 75.66 |
Price Performance
Historical ComparisonAbout AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About TTI Tetra Technologies Inc.
Tetra Technologies Inc is a diversified oil and gas services company, focused on completion fluids and associated products and services, water management, frac flowback, production well testing, offshore rig cooling, and compression services. It has two reporting segments namely Completion Fluids & Products, and Water & Flowback Services. The Completion Fluids & Products Division manufactures and markets clear brine fluids, additives, and associated products and services. Majority of revenue is from Completion Fluids & Products. The company derives maximum revenue from United states.